Attenuation of glucocorticoid signaling through targeted degradation of p300 via the 26S proteasome pathway

Molecular Endocrinology

Volumn 16, Issue 12, 2002, Pages 2819-2827

  Li, Qiao ^a,b   Su, Anna ^b   Chen, Jihong ^b   Lefebvre, Yvonne A ^a,b   Haché, Robert J G ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUTYRIC ACID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P300; STEROID RECEPTOR COACTIVATOR 1;

ACETYLATION; ARTICLE; CHROMATIN; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSCRIPTION REGULATION;

ACETYLATION; ACETYLTRANSFERASES; ANIMALS; BUTYRATES; CELL CYCLE PROTEINS; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CYSTEINE PROTEINASE INHIBITORS; DEXAMETHASONE; ENZYME INHIBITORS; GENE DELETION; GENE EXPRESSION; GENES, REPORTER; GLUCOCORTICOIDS; HELA CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; LEUPEPTINS; MAMMARY TUMOR VIRUS, MOUSE; PEPTIDE HYDROLASES; PROMOTER REGIONS (GENETICS); PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RECEPTORS, GLUCOCORTICOID; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 12244286738     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0154     Document Type: Article

References (56)

1. Wolffe AP, Collingwood TN, Li Q, Yee J, Urnov F, Shi YB 2000 Thyroid hormone receptor, v-ErbA, and chromatin. Vitam Horm 58:449-492
2. Bannister AJ, Kouzarides T 1996 The CBP co-activator is a histone acetyltransferase. Nature 384:641-643
3. Mizzen CA, Yang XJ, Kokubo T, Brownell JE, Bannister AJ, Owen-Hughes T, Workman J, Wang L, Berger SL, Kouzarides T, Nakatani Y, Allis CD 1996 The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87:1261-1270
4. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y 1996 The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959
5. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y 1996 A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324
6. Li Q, Herrler M, Landsberger N, Kaludov N, Ogryzko VV, Nakatani Y, Wolffe AP 1998 Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J 17:6300-6315
7. Li Q, Imhof A, Collingwood TN, Urnov FD, Wolffe AP 1999 p300 stimulates transcription instigated by ligand-bound thyroid hormone receptor at a step subsequent to chromatin disruption. EMBO J 18:5634-5652
8. Zhang W, Bieker JJ 1998 Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci USA 95:9855-9860
9. Boyes J, Byfield P, Nakatani Y, Ogryzko V 1998 Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396:594-598
10. Gu W, Roeder RG 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606
11. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM 1999 Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-686
12. Freeman BC, Yamamoto KR 2001 Continuous recycling: A mechanism for modulatory signal transduction. Trends Biochem Sci 26:285-290
13. Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357
14. Yao TP, Ku G, Zhou N, Scully R, Livingston DM 1996 The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci USA 93:10626-10231
15. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM 1996 Role of CBP/P300 in nuclear receptor signalling. Nature 383:99-103
16. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, Mullen TM, Glass CK, Rosenfeld MG 1998 Transcription factor-specific requirements for co-activators and their acetyltransferase functions. Science 279:703-707
17. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, Calomme C, Burny A, Nakatani Y, Jeang KT, Benkirane M, Van Lint C 1999 HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 18:6106-6118
18. Yang J, Kawai Y, Hanson RW, Arinze IJ 2001 Sodium butyrate induces transcription from the G α(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem 276:25742-25752
19. McKnight GS, Hager L, Palmiter RD 1980 Butyrate and related inhibitors of histone deacetylation block the induction of egg white genes by steroid hormones. Cell 22:469-477
20. Tichonicky L, Santana-Calderon MA, Defer N, Giesen EM, Beck G, Kruh J 1981 Selective inhibition by sodium butyrate of glucocorticoid-induced tyrosine aminotransferase synthesis in hepatoma tissue-cultured cells. Eur J Biochem 120:427-433
21. Bartsch J, Truss M, Bode J, Beato M 1996 Moderate increase in histone acetylation activates the mouse mammary tumor virus promoter and remodels its nucleosome structure. Proc Natl Acad Sci USA 93:10741-10746
22. Bresnick EH, John S, Berard DS, LeFebvre P, Hager GL 1990 Glucocorticoid receptor-dependent disruption of a specific nucleosome on the mouse mammary tumor virus promoter is prevented by sodium butyrate. Proc Natl Acad Sci USA 87:3977-3981
23. Lambert JR, Nordeen SK 1998 Steroid-selective initiation of chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter is controlled by the site of promoter integration. J Biol Chem 273:32708-32714
24. Wilson MA, Ricci AR, Deroo BJ, Archer TK 2002 The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo. J Biol Chem 277:15171-15181
25. Sheldon LA, Becker M, Smith CL 2001 Steroid hormone receptor-mediated histone deacetylation and transcription at the mouse mammary tumor virus promoter. J Biol Chem 276:32423-32426
26. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL 1994 Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771
27. Ciechanover A 1998 The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 17:7151-7160
28. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A 1999 Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96:12436-12441
29. Lam YA, Pickart CM, Alban A, Landen M, Jamieson C, Ramage R, Mayer RJ, Layfield R 2000 Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 97:9902-9906
30. Turnell AS, Grand RJ, Gorbea C, Zhang X, Wang W, Mymryk JS, Gallimore PH 2000 Regulation of the 26S proteasome by adenovirus E1A. EMBO J 19:4759-4773
31. Petersen BO, Wagener C, Marinoni F, Kramer ER, Melixetian M, Denchi EL, Gieffers C, Matteucci C, Peters JM, Helin K 2000 Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes Dev 14:2330-2343
32. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW 2000 Activation of HIF1 α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97:10430-10435
33. Molinari E, Gilman M, Natesan S 1999 Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo. EMBO J 18:6439-6447
34. Musti AM, Treier M, Bohmann D 1997 Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275:400-402
35. Thomas D, Tyers M 2000 Transcriptional regulation: Kamikaze activators. Curr Biol 10:R341-R343
36. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862
37. Lange CA, Shen T, Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97:1032-1037
38. Dace A, Zhao L, Park KS, Furono T, Takamura N, Nakanishi M, West BL, Hanover JA, Cheng S 2000 Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA 97:8985-8990
39. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939-948
40. Poizat C, Sartorelli V, Chung G, Kloner RA, Kedes L 2000 Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol Cell Biol 20:8643-8654
41. Salghetti SE, Caudy AA, Chenoweth JG, Tansey WP 2001 Regulation of transcriptional activation domain function by ubiquitin. Science 293:1651-1653
42. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, Gerritsen ME, Collins T 1998 Nuclear integration of glucocorticoid receptor and nuclear factor-κB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 273:29291-29294
43. Chakravarti D, Ogryzko V, Kao HY, Nash A, Chen H, Nakatani Y, Evans RM 1999 A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96:393-403
44. Wang HG, Rikitake Y, Carter MC, Yaciuk P, Abraham SE, Zerler B, Moran E 1993 Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J Virol 67:476-488
45. Candido EP, Reeves R, Davie JR 1978 Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105-113
46. Riggs MG, Whittaker RG, Neumann JR, Ingram VM 1977 n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462-464
47. Yoshida M, Kijima M, Akita M, Beppu T 1990 Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179
48. Lee DH, Goldberg AL 1998 Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol 8:397-403
49. Truss M, Bartsch J, Schelbert A, Haché RJ, Beato M 1995 Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo. EMBO J 14:1737-1751
50. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852
51. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2001 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat Cell Biol 3:15-23
52. Deroo BJ, Rentsch C, Sampath S, Young J, DeFranco DB, Archer TK 2002 Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol Cell Biol 22:4113-4123
53. Kraus WL, Kadonaga JT 1998 p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 12:331-342
54. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH, Kedes L, Wang JY, Graessmann A, Nakatani Y, Levrero M 1997 Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1:35-45
55. Cato AC, Weinmann J 1988 Mineralocorticoid regulation of transcription of transfected mouse mammary tumor virus DNA in cultured kidney cells. J Cell Biol 106:2119-2125
56. Pearce D, Yamamoto KR 1993 Mineralocorticoid and glucocorticoid receptor activities distinguished by non-receptor factors at a composite response element. Science 259:1161-1165